Table 1 Baseline demographics of the patients.

From: Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone

 

Maintained weight* (n = 161, 74.9%)

Reduced weight** (n = 54, 25.1%)

P-value

Age (years)

71.2 ± 7.2

73.8 ± 7.7

0.032

Sex

Male

134 (83.2%)

41 (75.9%)

0.233

Female

27 (16.8%)

13 (24.1%)

BMI (kg/m2)

24.4 ± 2.9

23.0 ± 2.9

0.002

Baseline body weight (kg)

65.3 ± 9.3

60.1 ± 9.0

 < 0.001

Smoking history

Never smoker

35 (21.7%)

11 (20.4%)

0.692

Ever smoker

126 (78.3%)

43 (79.6%)

Comorbidities

Hypertension

48 (29.8%)

12 (22.2%)

0.282

Diabetes mellitus

41 (25.5%)

12 (22.2%)

0.635

COPD

21 (13.0%)

2 (3.7%)

0.055

Malignancy

23 (14.3%)

3 (5.6%)

0.089

Pulmonary function test

FVC (% of predicted)

81.1 ± 15.5

71.1 ± 16.8

 < 0.001

DLCO (% of predicted)

72.0 ± 20.5

62.3 ± 20.7

0.004

Pirfenidone treatment

Dose adjustment

56 (34.8%)

19 (35.2%)

0.957

  1. Data are expressed as mean ± standard deviation or counts (%).
  2. BMI body mass index, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, COPD chronic obstructive pulmonary disease.
  3. *Maintained weight group is weight gain or weight loss < 5%/year, **Reduced weight group is weight loss ≥ 5%/year.
Back to article page